These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10170303)

  • 1. Identifying and managing patients with hyperlipidemia.
    Clark AB; Holt JM
    Am J Manag Care; 1997 Aug; 3(8):1211-9; quiz 1223-5. PubMed ID: 10170303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of dyslipidemia in adults.
    Ahmed SM; Clasen ME; Donnelly JE
    Am Fam Physician; 1998 May; 57(9):2192-2204, 2207-8. PubMed ID: 9606309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common questions in managing hyperlipidemia.
    Rosen IM; Sams RW
    Prim Care; 2006 Dec; 33(4):903-21. PubMed ID: 17169673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of antilipidemic therapies in chronic renal allograft failure.
    Wanner C; Bartens W; Galle J
    Kidney Int Suppl; 1995 Dec; 52():S60-2. PubMed ID: 8587286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for diagnosis and treatment of hyperlipidemia.
    Erkelens DW
    Ther Umsch; 1990 Jun; 47(6):443-7. PubMed ID: 2197753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing drug therapy for patients with hyperlipidemia.
    Safeer RS; Lacivita CL
    Am Fam Physician; 2000 Jun; 61(11):3371-82. PubMed ID: 10865931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of currently available modes of therapy in reaching lipid goals.
    Spratt KA; Denke MA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S14-6. PubMed ID: 15467019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering therapy today: treating the high-risk cardiovascular patient.
    Berra K
    J Cardiovasc Nurs; 2008; 23(5):414-21. PubMed ID: 18728514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN; Stalenhoef AF
    J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.